SCL Science Inc.

As of June 30, 2026, SCL Science Inc. carries a market capitalization of 57.14B, placing it among publicly traded companies globally. Its enterprise value stands at 80.69B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, SCL Science Inc. has 34.01M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.52, and the price-to-book ratio stands at 2.37.

As of June 30, 2026, SCL Science Inc. trades at an EV/EBITDA multiple of 26.96 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 80.69B versus a market cap of 57.14B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, SCL Science Inc. maintains a current ratio of 0.57, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 128.64, indicating elevated leverage, while an interest coverage ratio of 1.03 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SCL Science Inc. posted a negative return on equity (ROE) of -13.54, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.91, reflecting losses generated across the asset base. The company generates approximately 221.02M in revenue per employee across its workforce of 138.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 13.90 indicates how many times SCL Science Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, SCL Science Inc. recorded 17.25M in income tax expense. The company reported a pretax loss of -4.47B and -3.38B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, SCL Science Inc.'s stock has declined approximately 9.80% over the past 52 weeks. The 50-day moving average sits at 2,310.88, while the 200-day moving average is 2,054.40.

Over the twelve months ended June 30, 2026, SCL Science Inc. generated 30.50B in revenue and converted that into -3.38B in net income, yielding earnings per share of -138.70. EBITDA reached 2.99B, while operating income came in at -920.62M.

As of June 30, 2026, SCL Science Inc. holds 4.70B in cash and equivalents against 29.46B in total debt, resulting in a net debt position of 20.42B. Total book value stands at 24.11B, with working capital of -17.98B providing operational flexibility.

SCL Science Inc. produced 686.13M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.70B in capital expenditures, free cash flow totaled -3.02B - equivalent to -109.24 per share.

Over the twelve months ended June 30, 2026, SCL Science Inc. posted a gross margin of 22.95, reflecting its pricing power and cost economics. The operating margin of -3.02 and net profit margin of -11.09 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -6.50: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.59, meaning SCL Science Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

SCL Science Inc.'s most recent stock split took place on June 30, 2025 with a 1:4 split ratio.

As of June 30, 2026, SCL Science Inc. has an Altman Z-Score of -0.42, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.